As studied earlier, wild-type p53 expression opposes NF-κB function and inhibits tumorigenesis, and around half of human cancers exhibit p53 mutations (or have lost the wild-type allele) and, thus, activate the NF-κB pathway during the development of tumors. This evidence concerns the gene TP53 and cancer.